Title Slide
Faculty Presentations
| COVID Pneumonia |
Fig. 01 -
Title Slide
Fig. 02 -
Disclosures
Fig. 03 -
Agenda
Fig. 04 -
Pathophysiology, mechanisms of hypoxemia
Fig. 05 -
Acute Disease 1
Fig. 06 -
Treatment Decisions
Fig. 07 -
Hypoxia and Lung Failure
Fig. 08 -
Inflammatory mechanisms
Fig. 09 -
Acute Disease 4
Fig. 10 -
Arterial Filling Defects
Fig. 11 -
Tricompartmental Model
Fig. 12 -
High Flow Nasal Cannula
Fig. 13 -
Variants of Concern
Fig. 14 -
Important Clinical Trials
Fig. 15 -
Remdesivir
Fig. 16 -
Placebo vs Remdesivir
Fig. 17 -
Time to Recovery
Fig. 18 -
Corticosteroid Treatment
Fig. 19 -
Dexamethasone
Fig. 20 -
Mortality in 28 Days
Fig. 21 -
Effect of Dexamethasone
Fig. 22 -
Recovery Trial
Fig. 23 -
Corticosteroids and Mortality
Fig. 24 -
Corticosteroids and 28-Day Mortality
Fig. 25 -
Patient Characteristics
Fig. 26 -
IL-6 Antagonists and Mortality
Fig. 27 -
IL-6 Antagonists vs Placebo
Fig. 28 -
3 Outcomes
Fig. 29 -
Baricitinib plus Remdesivir
Fig. 30 -
Cumulative Recoveries
Fig. 31 -
Time to Recovery
Fig. 32 -
Helmet NIV vs High-Flow Nasal Oxygen
Fig. 33 -
Trial Helmet NIV
Fig. 34 -
Intubation Cumulative Incidence
Fig. 35 -
Intermediate vs Standard Dose
Fig. 36 -
Therapeutic versus Prophylactic
Fig. 37 -
Therapeutic vs Prophylactic Chart
Fig. 38 -
Heparin Therapeutic Anticoagulation
Fig. 39 -
Demographic and Clinical Characteristics
Fig. 40 -
Noncritically Ill Patients
Fig. 41 -
Organ Support-Free Days
Fig. 42 -
Therapeutic-dose vs Usual-care
Fig. 43 -
Post COVID Clinic Cases
Fig. 44 -
1 Month After Discharge
Fig. 45 -
3 Month After Discharge
Fig. 46 -
Small Airways Disease
Fig. 47 -
Post COVID ARDS
Fig. 48 -
43 y.o. Male Case
Fig. 49 -
58 y.o. Male Case
Fig. 50 -
Our Publications
Fig. 51 -
Ventilatory Mechanics
Fig. 52 -
Retrospective Cohort Study
Fig. 53 -
BV5(ml) vs Healthy Control
Fig. 54 -
BV5(ml) vs BV10(ml)
Fig. 55 -
Pulmonary Vascular Volumes
Fig. 56 -
Computerized Tomography of Chest
Fig. 57 -
Significant Dyspnea
Fig. 58 -
Thank You